ELUTIA INC.
NASDAQ: ELUT (Elutia, Inc.)
Last update: 5 hours ago0.876
0.19 (27.19%)
| Previous Close | 0.689 |
| Open | 0.780 |
| Volume | 956,184 |
| Avg. Volume (3M) | 361,309 |
| Market Cap | 37,397,696 |
| Price / Sales | 1.42 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -168.23% |
| Operating Margin (TTM) | -88.72% |
| Diluted EPS (TTM) | -1.32 |
| Quarterly Revenue Growth (YOY) | -9.90% |
| Current Ratio (MRQ) | 0.810 |
| Operating Cash Flow (TTM) | -28.90 M |
| Levered Free Cash Flow (TTM) | -10.41 M |
| Return on Assets (TTM) | -38.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Elutia, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.67 |
|
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women’s Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 2.27% |
| % Held by Institutions | 72.64% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Knollwood Investment Advisory, Llc | 30 Sep 2025 | 1,031,567 |
| Birchview Capital, Lp | 30 Sep 2025 | 711,175 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones |
| 09 Jan 2026 | Announcement | Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery |
| 06 Nov 2025 | Announcement | Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development |
| 23 Oct 2025 | Announcement | Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 |
| 14 Oct 2025 | Announcement | Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |